

| Medigen Biotechnology Corp. (3176 MEDIGEN) | | | | | |
|--|---|------------------------|--------------|----------------------|----------|
| SEQ_NO | 1 | Date of announcement | 2023/12/01 | Time of announcement | 14:48:08 |
| Subject | The Ministry of Health and Welfare has approved the collaborative autologous Gamma-Delta T cell therapy project by the Company and Hualien Tzu Chi Hospital | | | | |
| Date of events | 2023/12/01 | To which item it meets | paragraph 53 | | |
| Statement | <p>1.Date of occurrence of the event:2023/12/01</p> <p>2.Company name: Medigen Biotechnology Corp. (Medigen)</p> <p>3.Relationship to the Company (please enter “head office” or “subsidiaries”): head office</p> <p>4.Reciprocal shareholding ratios: N/A</p> <p>5.Cause of occurrence: Medigen, in collaboration with Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation (hereinafter as “Hualien Tzu Chi Hospital”), has applied for the autologous Gamma-Delta T (Magicell-GDT) cell therapy project. On 1st of December, 2023, Medigen received the approval letter from the competent authority, the Ministry of Health and Welfare, confirming that Medigen's Cell Processing Unit is compliant with Good Tissue Practice (GTP). In accordance with the regulations of the "Regulations Governing the Application of Specific Medical Examination Technique and Medical Device", the Magicell-GDT cells produced at Medigen’s Cell Processing Unit can be used for treating stage IV solid tumors at Hualien Tzu Chi Hospital.</p> <p>6. Countermeasures: The announcement was released in accordance with the approval letter of the Ministry of Health and Welfare.</p> <p>7. Any other matters that need to be specified (the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): (1) Details on the approved items in the abovementioned Hualien Tzu Chi Hospital cell therapy project:</p> <p style="padding-left: 20px;">A. Type of cell therapy: Autologous Gamma-Delta T cell (Magicell-GDT)</p> <p style="padding-left: 20px;">B. Indication: Stage IV solid tumor; Lung cancer, breast cancer, kidney cancer, prostate cancer, pancreatic cancer, colorectal cancer</p> <p style="padding-left: 20px;">C. Cell processing unit: Medigen’s cell processing unit</p> <p style="padding-left: 20px;">D. Approval period: From 2023/11/30 to 2026/02/02</p> | | | | |

| | |
|--|--|
| | <p>(2) The manufacturing technology of this approved Gamma-Delta T cell is exclusively licensed from the Japanese listed company MEDINET Co., Ltd (please see Medigen's announcement released on 7th October, 2019)</p> |
|--|--|

